Hema Dave
Impact in
-
- CAR-T cell therapy research
- Polyomavirus and related diseases
-
- Hematopoietic Stem Cell Transplantation
Papers in
- Oncology 20
- CAR-T cell therapy research 11
- Polyomavirus and related diseases 5
-
- Lymphoma Diagnosis and Treatment 8
- Co-authors
- Catherine M. Bollard (13 shared papers)Miriam R. Anver (2 shared papers)Donna Butcher (2 shared papers)Patrick J. Hanley (6 shared papers)Elizabeth J. Shpall (4 shared papers)Alan S. Wayne (2 shared papers)Carolina Colli Cruz (2 shared papers)Patrick O. Brown (1 shared paper)
- Journals
- Blood (5 papers)Blood Advances (3 papers)Molecular Therapy — Methods & Clinical Development (2 papers)Journal of Clinical Oncology (2 papers)Cytotherapy (2 papers)
- Partner nations
- United StatesCanadaNetherlands
In The Last Decade
Hema Dave
24 papers receiving 239 citations
Peers
Comparison fields: 5 of 43
- Oncology 150
- Hematology 34
- Immunology 56
- Genetics 21
- Genetics 50
Countries citing papers authored by Hema Dave
This map shows the geographic impact of Hema Dave's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hema Dave with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hema Dave more than expected).
Fields of papers citing papers by Hema Dave
This network shows the impact of papers produced by Hema Dave. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hema Dave. The network helps show where Hema Dave may publish in the future.
Co-authors
The 25 scholars most cited alongside Hema Dave, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 40 | |
| 2 | 2017 | 35 | |
| 3 | 2019 | 33 | |
| 4 | 2019 | 19 | |
| 5 | 2021 | 16 | |
| 6 | 2021 | 13 | |
| 7 | 2021 | 13 | |
| 8 | 2017 | 11 | |
| 9 | 2019 | 10 | |
| 10 | 2013 | 8 | |
| 11 | 2019 | 7 | |
| 12 | 1988 | 6 | |
| 13 | 2023 | 6 | |
| 14 | 2014 | 5 | |
| 15 | 2023 | 3 | |
| 16 | 2020 | 3 | |
| 17 | 2021 | 3 | |
| 18 | 2021 | 2 | |
| 19 | 2019 | 2 | |
| 20 | Rituximab for the treatment of relapsing/refractory thrombotic thrombocytopenic purpura (TTP) | 2002 | 1 |
About Hema Dave
Hema Dave is a scholar working on Oncology, Pathology and Forensic Medicine, Immunology, Genetics and Public Health, Environmental and Occupational Health, having authored 27 papers that have together received 241 indexed citations. Recurring topics across this work include CAR-T cell therapy research (11 papers), Lymphoma Diagnosis and Treatment (8 papers), Polyomavirus and related diseases (5 papers), Virus-based gene therapy research (4 papers), Acute Lymphoblastic Leukemia research (4 papers), Immunotherapy and Immune Responses (4 papers), Immune Cell Function and Interaction (3 papers) and Cytomegalovirus and herpesvirus research (3 papers). The work is most often cited by research in Oncology (150 citations), Hematology (34 citations), Immunology (56 citations), Genetics (21 citations) and Genetics (50 citations). Hema Dave has collaborated with scholars based in United States, Canada and Netherlands. Frequent co-authors include Catherine M. Bollard, Miriam R. Anver, Donna Butcher, Patrick J. Hanley, Elizabeth J. Shpall, Alan S. Wayne, Carolina Colli Cruz, Patrick O. Brown, Sivasubramanian Baskar and Javed Khan. Their work appears in journals such as Blood, Blood Advances, Molecular Therapy — Methods & Clinical Development, Journal of Clinical Oncology and Cytotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.